EyePoint Pharmaceuticals Announces Presentation of Data Highlighting YUTIQ™ for Posterior Segment Uveitis at the 36th Annual ...
YUTIQ™ delivers positive twelve month efficacy vs sham with reduced rates of recurrence and reduced use of rescue therapies in patients with noninfectious posterior segment uveitis NDA currently under review by FDA; PDUFA action date of November 5, 2018 …